Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations: 2023-2024

  • Anika Therapeutics' Liabilities from Discontinued Operations fell 61.83% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 61.83%. This contributed to the annual value of $4.1 million for FY2024, which is 61.83% down from last year.
  • Latest data reveals that Anika Therapeutics reported Liabilities from Discontinued Operations of $4.1 million as of Q4 2024, which was down 61.83% from $10.8 million recorded in Q4 2023.
  • In the past 5 years, Anika Therapeutics' Liabilities from Discontinued Operations ranged from a high of $10.8 million in Q4 2023 and a low of $4.1 million during Q4 2024.
  • Moreover, its 2-year median value for Liabilities from Discontinued Operations was $7.5 million (2023), whereas its average is $7.5 million.
  • Data for Anika Therapeutics' Liabilities from Discontinued Operations shows a maximum YoY tumbled of 61.83% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Anika Therapeutics' Liabilities from Discontinued Operations stood at $10.8 million in 2023, then slumped by 61.83% to $4.1 million in 2024.